JPWO2020210551A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020210551A5 JPWO2020210551A5 JP2021559435A JP2021559435A JPWO2020210551A5 JP WO2020210551 A5 JPWO2020210551 A5 JP WO2020210551A5 JP 2021559435 A JP2021559435 A JP 2021559435A JP 2021559435 A JP2021559435 A JP 2021559435A JP WO2020210551 A5 JPWO2020210551 A5 JP WO2020210551A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 185
- 102000004965 antibodies Human genes 0.000 claims description 66
- 108090001123 antibodies Proteins 0.000 claims description 66
- 230000027455 binding Effects 0.000 claims description 64
- 239000000427 antigen Substances 0.000 claims description 51
- 102000038129 antigens Human genes 0.000 claims description 51
- 108091007172 antigens Proteins 0.000 claims description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 23
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 23
- 230000002401 inhibitory effect Effects 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 18
- 230000003042 antagnostic Effects 0.000 claims description 12
- 239000005557 antagonist Substances 0.000 claims description 12
- 208000009018 medullary Thyroid cancer Diseases 0.000 claims description 12
- 230000011664 signaling Effects 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 150000003384 small molecules Chemical class 0.000 claims description 10
- 201000005204 thyroid medullary carcinoma Diseases 0.000 claims description 10
- 102000000589 Interleukin-1 Human genes 0.000 claims description 8
- 108010002352 Interleukin-1 Proteins 0.000 claims description 8
- 101700001630 RET Proteins 0.000 claims description 8
- 102100006051 RET Human genes 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- -1 small molecule tyrosine kinase inhibitor Chemical class 0.000 claims description 8
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 6
- 210000004072 Lung Anatomy 0.000 claims description 6
- 229940053128 Nerve Growth Factor Drugs 0.000 claims description 6
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 6
- 208000004296 Neuralgia Diseases 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229960003787 sorafenib Drugs 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 206010073153 Familial medullary thyroid cancer Diseases 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- 206010024324 Leukaemias Diseases 0.000 claims description 4
- 206010073148 Multiple endocrine neoplasia Type 2A Diseases 0.000 claims description 4
- 206010029098 Neoplasm skin Diseases 0.000 claims description 4
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 4
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 4
- 208000009955 Thyroid Neoplasms Diseases 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 230000000202 analgesic Effects 0.000 claims description 4
- 230000002222 downregulating Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 201000006850 familial medullary thyroid carcinoma Diseases 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 201000005170 papillary thyroid carcinoma Diseases 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- 210000004881 tumor cells Anatomy 0.000 claims description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 4
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 claims description 4
- JGSMCYNBVCGIHC-NTUHNPAUSA-N (3E)-3-[(4-hydroxyphenyl)methylidene]-5,6-dimethoxy-1H-indol-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)\C1=C\C1=CC=C(O)C=C1 JGSMCYNBVCGIHC-NTUHNPAUSA-N 0.000 claims description 2
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3E)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 claims description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims description 2
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 claims description 2
- FGTCROZDHDSNIO-UHFFFAOYSA-N 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)C1=C(NCC=2C3=CC=CC=C3N=CC=2)C=CS1 FGTCROZDHDSNIO-UHFFFAOYSA-N 0.000 claims description 2
- HXHAJRMTJXHJJZ-UHFFFAOYSA-N 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Br)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCC1 HXHAJRMTJXHJJZ-UHFFFAOYSA-N 0.000 claims description 2
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 claims description 2
- QFCXANHHBCGMAS-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(COC=2C=3OC=CC=3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 QFCXANHHBCGMAS-UHFFFAOYSA-N 0.000 claims description 2
- CTNPALGJUAXMMC-PMFHANACSA-N 5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide Chemical compound C([C@@H](O)CNC(=O)C=1C(C)=C(\C=C/2C3=CC(F)=CC=C3NC\2=O)NC=1C)N1CCOCC1 CTNPALGJUAXMMC-PMFHANACSA-N 0.000 claims description 2
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 claims description 2
- 102100000269 AIMP2 Human genes 0.000 claims description 2
- 208000005298 Acute Pain Diseases 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 206010003246 Arthritis Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 208000000003 Breakthrough Pain Diseases 0.000 claims description 2
- 208000000409 Breast Neoplasms Diseases 0.000 claims description 2
- 102100006374 CASP1 Human genes 0.000 claims description 2
- 102100014205 CHUK Human genes 0.000 claims description 2
- 101710002883 CHUK Proteins 0.000 claims description 2
- 108060001945 CRK Proteins 0.000 claims description 2
- ONIQOQHATWINJY-UHFFFAOYSA-N Cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 2
- 206010058019 Cancer pain Diseases 0.000 claims description 2
- 108090000426 Caspase 1 Proteins 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000006561 Cluster Headache Diseases 0.000 claims description 2
- 208000001636 Diabetic Neuropathy Diseases 0.000 claims description 2
- 206010012680 Diabetic neuropathy Diseases 0.000 claims description 2
- 229960001433 Erlotinib Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000004404 Intractable Pain Diseases 0.000 claims description 2
- UHEBDUAFKQHUBV-UHFFFAOYSA-N JSPY-st000261 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCOC(=O)CN(C)C)C4=C3CC2=C1 UHEBDUAFKQHUBV-UHFFFAOYSA-N 0.000 claims description 2
- 208000009883 Joint Disease Diseases 0.000 claims description 2
- 229940054136 Kineret Drugs 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims description 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N Lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims description 2
- 208000000214 Leukemia, Myelomonocytic, Chronic Diseases 0.000 claims description 2
- MPVGZUGXCQEXTM-UHFFFAOYSA-N Linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025650 Malignant melanoma Diseases 0.000 claims description 2
- 206010027599 Migraine Diseases 0.000 claims description 2
- 208000008085 Migraine Disorders Diseases 0.000 claims description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 2
- 229950003968 Motesanib Drugs 0.000 claims description 2
- RAHBGWKEPAQNFF-UHFFFAOYSA-N Motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 claims description 2
- 208000006876 Multiple Endocrine Neoplasia Type 2b Diseases 0.000 claims description 2
- 206010073149 Multiple endocrine neoplasia Type 2 Diseases 0.000 claims description 2
- 206010053643 Neurodegenerative disease Diseases 0.000 claims description 2
- XZXHXSATPCNXJR-ZIADKAODSA-N Nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims description 2
- 229940005483 OPIOID ANALGESICS Drugs 0.000 claims description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 2
- 206010036376 Post herpetic neuralgia Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 208000000399 Procedural Pain Diseases 0.000 claims description 2
- 206010039083 Rhinitis Diseases 0.000 claims description 2
- 208000008765 Sciatica Diseases 0.000 claims description 2
- 108020004459 Small Interfering RNA Proteins 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- SPMVMDHWKHCIDT-UHFFFAOYSA-N Tivozanib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 claims description 2
- 208000004371 Toothache Diseases 0.000 claims description 2
- 206010044652 Trigeminal neuralgia Diseases 0.000 claims description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N Vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 2
- 229950000578 Vatalanib Drugs 0.000 claims description 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N Vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 2
- 208000009935 Visceral Pain Diseases 0.000 claims description 2
- 102100013671 ZHX2 Human genes 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 230000001154 acute Effects 0.000 claims description 2
- 229960004238 anakinra Drugs 0.000 claims description 2
- 239000000611 antibody drug conjugate Substances 0.000 claims description 2
- 108091008116 antibody drug conjugates Proteins 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 201000008848 bladder disease Diseases 0.000 claims description 2
- 229960001292 cabozantinib Drugs 0.000 claims description 2
- 229960002412 cediranib Drugs 0.000 claims description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 2
- 230000003412 degenerative Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000003828 downregulation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- 201000005569 gout Diseases 0.000 claims description 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- 229930014694 morphine Natural products 0.000 claims description 2
- 230000000955 neuroendocrine Effects 0.000 claims description 2
- 229960004378 nintedanib Drugs 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims description 2
- 230000003364 opioid Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- 108091007921 receptor tyrosine kinases Proteins 0.000 claims description 2
- 102000027656 receptor tyrosine kinases Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 229960001886 rilonacept Drugs 0.000 claims description 2
- 108010046141 rilonacept Proteins 0.000 claims description 2
- 101700005382 rpi-1 Proteins 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 239000002924 silencing RNA Substances 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- 201000010874 syndrome Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 229960000241 vandetanib Drugs 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims 1
- 102000004329 Glial cell line-derived neurotrophic factor Human genes 0.000 description 10
- 108090000821 Glial cell line-derived neurotrophic factor Proteins 0.000 description 10
- 230000001404 mediated Effects 0.000 description 8
- 102100012672 ARTN Human genes 0.000 description 5
- 101700061329 ARTN Proteins 0.000 description 5
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 5
- 101700080346 artM Proteins 0.000 description 5
- 230000003993 interaction Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000000903 blocking Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 102000024926 GDNF family Human genes 0.000 description 2
- 108091020536 GDNF family Proteins 0.000 description 2
- 102100015653 NRTN Human genes 0.000 description 2
- 108010015406 Neurturin Proteins 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 102100018019 PSPN Human genes 0.000 description 1
- 108091007878 RET receptors Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 108010070453 persephin Proteins 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000646 scanning calorimetry Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024002528A JP2024024114A (ja) | 2019-04-10 | 2024-01-11 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832218P | 2019-04-10 | 2019-04-10 | |
| US62/832,218 | 2019-04-10 | ||
| PCT/US2020/027554 WO2020210551A1 (fr) | 2019-04-10 | 2020-04-09 | Anticorps humains qui se lient au ret et leurs procédés d'utilisation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002528A Division JP2024024114A (ja) | 2019-04-10 | 2024-01-11 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527373A JP2022527373A (ja) | 2022-06-01 |
| JPWO2020210551A5 true JPWO2020210551A5 (fr) | 2023-01-10 |
| JP7511576B2 JP7511576B2 (ja) | 2024-07-05 |
Family
ID=70554175
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559435A Active JP7511576B2 (ja) | 2019-04-10 | 2020-04-09 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
| JP2024002528A Pending JP2024024114A (ja) | 2019-04-10 | 2024-01-11 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002528A Pending JP2024024114A (ja) | 2019-04-10 | 2024-01-11 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220185900A1 (fr) |
| EP (1) | EP3953390A1 (fr) |
| JP (2) | JP7511576B2 (fr) |
| KR (1) | KR20210150509A (fr) |
| CN (1) | CN113993898A (fr) |
| AU (1) | AU2020270966A1 (fr) |
| CA (1) | CA3134258A1 (fr) |
| IL (1) | IL287067A (fr) |
| MA (1) | MA55615A (fr) |
| MX (1) | MX2021012335A (fr) |
| WO (1) | WO2020210551A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023008327A (es) | 2021-01-15 | 2023-08-22 | Seagen Inc | Anticuerpos inmunomoduladores de anticuerpo-farmaco. |
| BR112023015561A2 (pt) | 2021-02-03 | 2023-11-14 | Univ Minnesota | Compostos imunoestimuiladores e conjugados |
| WO2023144790A1 (fr) * | 2022-01-31 | 2023-08-03 | Glaxosmithkline Intellectual Property (No.3) Limited | Prévention et traitement des maux de tête |
| WO2023215740A1 (fr) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Conjugués anticorps-médicament immunomodulateurs |
| WO2024030577A1 (fr) | 2022-08-03 | 2024-02-08 | Seagen Inc. | Conjugués anti-pd-l1-médicament immunostimulateurs |
| EP4321522A1 (fr) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Composés cytotoxiques et conjugués de ceux-ci |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (fr) | 2004-04-20 | 2005-11-03 | Genmab A/S | Anticorps monoclonaux humains diriges contre cd20 |
| JP2008546716A (ja) | 2005-06-17 | 2008-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗ＧＦＲα３抗体 |
| EP1941909A4 (fr) * | 2005-10-24 | 2012-05-23 | Takeda Pharmaceutical | Medicaments anticancereux |
| CN102585002A (zh) | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | 人il-6受体的高亲和力抗体 |
| DK2387583T3 (en) | 2009-01-14 | 2019-01-14 | Ablynx Nv | PULMONAL ADMINISTRATION OF VARIABLE IMMUNGLOBULIN SINGLE DOMAINS AND CONSTRUCTIONS THEREOF. |
| HUE035773T2 (en) | 2009-06-05 | 2018-05-28 | Ablynx Nv | Trivalent human airway giant cell virus (hrsv) nanotubes for preventing and / or treating respiratory infections |
| EP2445936A1 (fr) | 2009-06-26 | 2012-05-02 | Regeneron Pharmaceuticals, Inc. | Anticorps bispécifiques facilement isolés avec un format d'immunoglobuline native |
| JO3462B1 (ar) * | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
-
2020
- 2020-04-09 MA MA055615A patent/MA55615A/fr unknown
- 2020-04-09 AU AU2020270966A patent/AU2020270966A1/en active Pending
- 2020-04-09 CN CN202080042521.7A patent/CN113993898A/zh active Pending
- 2020-04-09 EP EP20724257.9A patent/EP3953390A1/fr active Pending
- 2020-04-09 WO PCT/US2020/027554 patent/WO2020210551A1/fr unknown
- 2020-04-09 MX MX2021012335A patent/MX2021012335A/es unknown
- 2020-04-09 KR KR1020217036432A patent/KR20210150509A/ko unknown
- 2020-04-09 JP JP2021559435A patent/JP7511576B2/ja active Active
- 2020-04-09 US US17/602,562 patent/US20220185900A1/en active Pending
- 2020-04-09 CA CA3134258A patent/CA3134258A1/fr active Pending
-
2021
- 2021-10-07 IL IL287067A patent/IL287067A/en unknown
-
2024
- 2024-01-11 JP JP2024002528A patent/JP2024024114A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5899310B2 (ja) | ｃ−ＫＩＴ抗体およびその使用 | |
| CN110536903B (zh) | 抗ox40抗体及其用途 | |
| JP2021008487A (ja) | 抗ｎｋｇ２ａ抗体を使用した治療計画 | |
| CN105073133B (zh) | 抗gdf15抗体 | |
| JP2019030313A (ja) | ヒトｏｘ４０受容体に対する結合分子 | |
| US10124038B2 (en) | Modulators of syndecan-2 and uses thereof | |
| KR20230144099A (ko) | 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료 | |
| JP2011520885A (ja) | 抗ｃｘｃｒ４抗体 | |
| CN111182919A (zh) | 抗cd137抗体 | |
| TWI500629B (zh) | 介白素－６抗體及其用途 | |
| JP2024028805A (ja) | がん処置のための坑ｉｌ－８抗体及び坑ｐｄ－１抗体を用いる組合せ治療 | |
| JP2020510673A (ja) | がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法 | |
| US20200283518A1 (en) | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer | |
| US11440959B2 (en) | CD226 agonist antibodies | |
| JPWO2020210551A5 (fr) | ||
| JP2023502023A (ja) | Ｃｄ２００受容体アンタゴニスト結合分子 | |
| TW201716439A (zh) | Ｈｅｒ３抗體 | |
| CN115666724A (zh) | 通过施用pd-1抑制剂抗体西米普利单抗来治疗宫颈癌的方法 | |
| EP3164154A1 (fr) | Polythérapie | |
| JP6845237B2 (ja) | 抗−ヒトｉｌ−３抗体、ｉｌ−３の高められた発現又はレベルに関連する疾患又は機能障害へのそれらの使用、及びヒトｉｌ−３の検出方法へのそれらの使用 | |
| RU2021129250A (ru) | Человеческие антитела, связывающие ret, и способы их применения | |
| TWI845626B (zh) | 增進治療癌症功效的il-4/il-13途徑抑制劑 | |
| JP2018505144A (ja) | 抗ｃｘｃｌ１２抗体分子およびその使用 | |
| WO2024102962A1 (fr) | Anticorps bispécifiques cytotoxiques se liant à dr5 et muc16 et leurs utilisations |